Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Pharma.AI

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 1

  1. Insilico Medicine reports 2026 first-half profitability and AI pipeline progress

    Insilico Medicine announced profitability in the first half of 2026, according to a 36Kr report. The report says 35 pipeline assets developed with its generative-AI platform, Pharma.AI, reached preclinical candidate compound status, while disclosed business-development cooperation involving its AI platform and pipeline totaled US$11 billion. In the interview, co-CEO Ren Feng said 70%–80% of the company’s code is written by AI and that AI now has substantial weight in drug-development decisions. He also said automated laboratories still require manual validation and calibration before experiments can be run, and that current technology is insufficient for a fully autonomous research loop.

    36氪 人工智能 · 🔥 0

Experience and discussion from the community

Share my Pharma.AI experienceAsk about Pharma.AI

Nobody has shared their experience with Pharma.AI yet.